《大行報告》瑞銀上調統一企業中國(00220.HK)目標價至9.5元 評級「中性」
瑞銀發表報告表示,預期統一企業中國(00220.HK)未來三年銷售增長加快,主因公司有信心提升市佔率、改善改革後的渠道控制和產品組合升級等,惟短期而言,因原材料成本上升而加價可能性較低下,料其今年度純利按年下跌3.2%。
報告指,其現估值相當於明年預測企業價值對EBITDA倍數9倍,EBITDA在2021至2023年年均複合增長預測約8%,相對內地及香港同業而言,現估值合理。瑞銀降統一2021年度每股盈測4%,但升2022至2023年度每股盈測6%及11%,目標價由8.3元上調至9.5元,維持「中性」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.